Floatz logo

Lisinopril

Diabetic Nephropathy

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Diabetic Nephropathy cohort.

Asset / SponsorPhaseRating
Folic Acid
Fuling Central Hospital of Chongqing City
Phase 2/3BB
Spironolactone
Hospital de Messejana Dr. Carlos Alberto Studart Gomes
Phase 4BB
VALSARTAN
Columbia University
Phase 4BB
SIMVASTATIN
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB
Nifedipine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3BB

View all 18 →

Same molecule, other indications

Lisinopril is also rated in:

hypertensive disorderDormant
BB
Indicative ·
64 / 100
View asset →
Abdominal ObesityDormant
B
Indicative ·
62 / 100
View asset →
Becker muscular dystrophyDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →